Analytical evaluation of thirty-two SARS-CoV-2 lateral flow antigen tests demonstrates sensitivity remains with the SARS-CoV-2 Gamma lineage.

Konstantina Kontogianni (ORCID 0000-0002-5353-3682)*, Daisy Bengey (ORCID 0000-0002-0045-0218)*, Dominic Wooding, Kate Buist, Caitlin Greenland-Bews (0000-0003-3374-1385), Christopher T. Williams, Margaretha de Vos (ORCID 0000-0003-3059-2986), Camille Escadafal (ORCID 0000-0002-0268-750X), Emily R. Adams (ORCID 0000-0003-4058-4461), Thomas Edwards (ORCID 0000-0003-4058-4461), Ana I. Cubas-Atienzar (ORCID 0000-0002-9604-124X)**

Authors affiliations: Liverpool School of Tropical Medicine, Centre for Drugs and Diagnostics, Liverpool, United Kingdom (K. Kontogianni, D. Bengey, D. Wooding, K. Buist, C. Greenland-Bews, C.T. Williams, E.R. Adams, T. Edwards, A.I. Cubas-Atienzar); FIND, the global alliance for diagnostics, Geneva, Switzerland (M. de Vos, C. Escadafal); Mologic, Bedfordshire, United Kingdom (E.R. Adams)

Abstract

The limit of detection (LOD) of thirty-two antigen lateral flow tests (Ag-RDT) were evaluated with the SARS-CoV-2 Gamma variant. Twenty-eight of thirty-two Ag-RDTs exceeded the World Health Organization criteria of an LOD of 1.0x10⁶ genome copy numbers/ml and performance was equivalent as with the 2020 B.1 lineage and Alpha variant.

Main

The emergence of the variant of concern (VoC) Gamma (Pango P.1) began in November 2020 in the state of Amazonas in Brazil. The Gamma variant is estimated to be 1.7-2.4 times more transmissible than other local strains in Brazil (1) and quickly started to be detected at increasing rates from January 2021 onwards throughout the country, and became the predominant lineage associated with the second wave of infections with over 13 million confirmed cases and 350000 deaths (2). As of 30th of November 2021, this strain has spread to 90 countries, and remains one of the most prevalent circulating in the Americas, with highest frequency in South America. In South America, the proportion of Gamma associated cases range from 5% to 100% depending on the country. Countries with higher levels of circulation of Gamma variant include Saint Vincent and Grenadines (100%), Haiti (100%), Trinidad and Tobago (50%), Argentina (30%) and Venezuela (30%) followed by Chile, Brazil, Peru, Ecuador, Suriname with 10%-20% of the circulating SARS-CoV-2 variants being Gamma (3).

The use of antigen SARS-CoV-2 lateral flow diagnostic tests (Ag-RDT) has become one of the first lines of defense against COVID-19, enabling early identification and isolation of cases to slow transmission, provision of targeted care, and protection of health system.

Gamma has 21 mutations, including 10 in the Spike (S) and 3 in the Nucleocapsid (N) proteins. As SARS-CoV-2 Ag-RDTs target S or N proteins, there is concern that these mutations could affect Ag-RDT performance. Thus, we sought to evaluate the LOD of 32 commercially available

^{*}Contributed equally to this manuscript

^{**}Address correspondence to Ana I. Cubas-Atienzar: email Ana.CubasAtienzar@lstmed.ac.uk, phone 0044 (1) 51 705 3100

Ag-RDTs using the Gamma VoC, and to compare the results with previously determined LODs with Alpha and the ancestral B1 strain (5,7).

A clinical isolate from the P1 lineage of SARS-CoV-2 (hCoV-19/Japan/TY7-503/2021) was used for the evaluation. Briefly, the virus stock was propagated into Vero E6 cells (C1008; African green monkey kidney cells) that were maintained at 37°C with 5% CO₂ in Dulbecco's minimal essential medium (DMEM) supplemented with 4.5g/L glucose and L-Glutamine (Lonza, US), 10% foetal bovine serum (Sigma, US), and 50 units per ml of penicillin/streptomycin (Gibco, US). Frozen aliquots of the third passage of the virus were quantified via plaque assay as previously described (8).

The third passage was serially diluted in DMEM from $1.0x10^5$ to $1.0x10^2$ plaque forming units (pfu)/mL for determining the LODs of the 32 Ag-RDTs. The viral dilutions were added directly to the respective Ag-RDT extraction buffers, and Ag-RDTs were performed following the manufacturer instructions. Each dilution was tested in triplicate, with DMEM as a negative control. When the ten-fold LOD was found, two-fold dilutions were made and tested to confirm the lowest LOD (LLOD). The LOD was defined as the last dilution of a valid test where all three replicates were positive. Validity was determined by the presence of a control line, and only valid tests were included in the analysis. A positive result was interpreted visually by two operators by the presence of a test line. In the event of discordant result, a third operator read the test and acted as a tiebreaker.

RNA was extracted from each dilution using a QIAMP Viral RNA mini kit (Qiagen, Germany) and then genome copies (gcn)/mL were quantified using the COVID-19 Genesig RT-qPCR kit (PrimerDesign, UK) as previously described. We found 21/32 Ag-RDTs had an analytical LOD of $\leq 5.0 \times 10^2$ pfu/ml (ActiveXpress, Bioperfectus, Core Test, Espline, Genedia, Fortress, iChroma, InTec, Joysbio, LumiraDx, Nadal, NowCheck, Panbio, PerkinElmer, RightSign, Roche, Standard F, Standard Q, Strong Step, Sure-Status and Wantai) fulfilling the British Department of Health and Social Care (DHSC) acceptable criteria. Additionally, 28/32 (including Biocredit, Covid-go, Excalibur, Mologic, Tigsun and Wondfo) had an LOD of $\leq 1.0 \times 10^6$ gcn/ml fulfilling the recommendations in the WHO Target Product Profile for SARS-CoV-2 Ag-RDT (Table 1). The least sensitive tests with the Gamma variant were Innova, Flowflex, Hotgen, Onsite and RespiStrip.

Sensitivity to other SARS-CoV-2 strains was compared based on our previous work. There was no significant difference between the Ag-RDT LOD with Gamma in comparison to either the Alpha (Kruskal Wallis p = 0.315) or ancestral B.1 lineage (Kruskal Wallis p = 0.378) (Fig.1).

This is the most comprehensive analytical evaluation of COVID-19 Ag-RDTs with the Gamma VoC, and we have demonstrated that test performance is maintained, indicating Ag-RDT compatibility with this VoC. This evidence supports their continued usage in countries where the Gamma strain is circulating. However, clinical diagnostic evaluations in prospective cohorts in these localities are required to provide definitive data on their clinical performance. All the Ag-RDTs evaluated in this study detect the N protein, which contains fewer mutations than S in the Gamma lineage. Ag-RDTs targeting S may be affected differently. It is vital that diagnostic evaluations continue to monitor test performance in emerging variants, to ensure continued diagnostic performance.

Sources of funding: The study was supported by the global alliance for diagnostics (FIND).

Acknowledgements: We thank Grant L Hughes for facilitating the SARS-CoV-2 isolate.

Conflicts of Interest: E.R. Adams is an employee of Mologic. M. de Vos and C. Escadafal are employees of FIND. E.R. Adams and FIND had no role in data collection and analysis.

About the author

Konstantina Kontogianni is a research technician at the Liverpool School of Tropical Medicine, and her primary interest is the diagnosis of tuberculosis and respiratory viruses including SARS-CoV-2.

References

- 1. Duong D. Alpha, Beta, Delta, Gamma: What's important to know about SARS-CoV-2 variants of concern? CMAJ. 2021;
- 2. Nonaka CKV, Gräf T, Barcia CA de L, Costa VF, de Oliveira JL, Passos R da H, et al. SARS-CoV-2 variant of concern P.1 (Gamma) infection in young and middle-aged patients admitted to the intensive care units of a single hospital in Salvador, Northeast Brazil, February 2021. Int J Infect Dis. 2021;
- 3. Global Initiative on Sharing All Influenza Data, (GISAID). GISAID [Internet]. Available from: https://www.gisaid.org/hcov19-variants/
- 4. Osterman A, Iglhaut M, Lehner A, Späth P, Stern M, Autenrieth H, et al. Comparison of four commercial, automated antigen tests to detect SARS-CoV-2 variants of concern. Med Microbiol Immunol. 2021;
- 5. Kontogianni K, Cubas-Atienzar AI, Wooding D, Buist K, Thompson CR, Williams CT, et al. Lateral flow antigen tests can sensitively detect live cultured virus of the SARS-CoV-2 B1.1.7 lineage. Journal of Infection. 2021.
- 6. Sanches PRS, Charlie-Silva I, Braz HLB, Bittar C, Freitas Calmon M, Rahal P, et al. Recent advances in SARS-CoV-2 Spike protein and RBD mutations comparison between new variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil) and Delta (B.1.617.2, India). J Virus Erad. 2021;
- 7. Cubas-Atienzar, Ana I., Kontogianni K, Edwards T, Wooding D, Buist K, Thompson, Caitlin R. Williams CT, et al. Limit of detection in different matrices of 19 commercially available rapid antigen tests for the detection of SARS-CoV-2. Sci Rep. 2021;11(1):1–8.
- 8. Edwards T, Kay GA, Aljayyoussi G, Owen SI, Harland AR, Pierce NS, et al. SARS-CoV-2 Transmission Risk from sports Equipment (STRIKE). medRxiv. 2021;

Table 1. Description of the Ag-RDTs evaluated in this study and their LOD using the Gamma VoC.

In this Study	Test/Company/Country	Target Ag	LOD (pfu/ml)	LOD (gcn/ml)
ActiveXpress	ActivXpress+ COVID-19 Ag Complete Kit/Edinburgh Genetics Ltd./UK	N	5.0 x 10 ²	2.8 x 10 ⁵
Biocredit	Biocredit COVID-19 Ag/Rapigen Inc./Rep. Korea	N	1.0 x 10 ³	5.6 x 10 ⁵
Bioperfectus	SARS-CoV-2 Ag Rapid Test/ Jiangsu Bioperfectus Tech. Ltd./China	N	5.0 x 10 ¹	2.2 x 10 ⁴
Core Test	COVID-19 Ag Test/Core Technology Ltd./China	N	1.0x 10 ¹	3.1×10^3
Covid-Go	Covid-Go/Mologic Ltd./UK	N	1.0 x 10 ³	5.6 x 10 ⁵
Espline	ESPLINE SARS-CoV-2/Fujirebio Diagnostics Inc./Japan	N	5.0 x 10 ²	2.8 x 10 ⁵
Excalibur	Rapid SARS-CoV-2 Antigen test card/ Excalibur Healthcare Services/UK	N	1.0 x 10 ³	5.6 x 10 ⁵
Flowflex	Flowflex SARS-CoV-2 Ag Rapid Test/Acon Biotech, Ltd./China	N	2.5 x 10 ³	1.7 x 10 ⁶
Fortress	Coronavirus Ag Rapid test cassette/Zhejian Orient Gene Biotech/ China	N	5.0×10^2	2.8 x 10 ⁵
Genedia	GENEDIA W COVID-19 Ag/ Green Cross Medical Sciences/Rep. Korea	N	5.0 x 10 ²	2.8 x 10 ⁵
Hotgen	2019-nCoV Antigen test/ Beijin Hotgen Biotech Ltd./China	N	2.5 x 10 ³	1.7 x 10 ⁶
iChroma	iChroma COVID-19 Ag Test/ Boditech Medical Inc./Rep. Korea	N	1.0 x 10 ²	4.3×10^4
Innova	Innova SARS-CoV-2 Antigen Rapid/ Innova Medical Group Ltd./UK	N	2.5 x 10 ³	1.7 x 10 ⁶
InTec	Rapid SARS-CoV-2 Antigen test/Intec Products Inc./China	N	1.0x 10 ¹	3.1×10^3
Joysbio	SARS-CoV-2 Antigen Rapid Test Kit/ Joysbio Biotechnology Ltd./China	N	5.0 x 10 ²	2.8×10^5
LumiraDx	LumiraDx SARS-CoV-2 antigen test/ Lumira Dx Ltd./US	N	1.0 x 10 ²	4.3×10^4
Mologic	Mologic COVID-19 Ag Test device/ Mologic Ltd./UK	N	1.0 x 10 ³	5.6 x 10 ⁵
Nadal	Nadal COVID-19 Ag Test/Nal von minden GmbH/Germany	N	5.0 x 10 ²	2.8 x 10 ⁵
NowCheck	NowCheck COVID-19 Ag test/ Bionote Inc./ Rep. Korea	N	1.0 x 10 ²	4.3×10^4
Onsite	Onsite COVID-19 Ag Rapid Test/CTKBiotech Inc./USA	N	5.0 x 10 ³	3.5 x 10 ⁶
Panbio	Panbio COVID-19 Ag Rapid Test/Abbott Rapid Diagnostics/Rep. Korea	N	1.0 x 10 ²	4.3×10^4
PerkinElmer	PerkinElmer COVID-19 Antigen Test/PerkinElmer/ Switzerland	N	5.0×10^2	2.8 x 10 ⁵
RespiStrip	Respi-Strip COVID-19 Ag/Coris Bioconcept/Belgium	N	5.0 x 10 ³	3.5×10^6
RighSign	COVID-19 Antigen Rapid Test Cassette/Hangzhou Biotech Itd./China	N	2.5 x 10 ¹	1.1 x 10⁴
Roche	SARS-CoV-2 Rapid Ag Test/ Roche Diagnostics/Switzerland	N	5.0×10^2	2.8×10^5
StrongStep	StrongStep SARS-CoV-2 Ag Rapid Test/Nanjing Liming Bio-Products/US	N	5.0 x 10 ¹	2.2 x 10 ⁴
Standard F	Standard F COVID-19 Ag FIA., SD Biosensor Inc./Rep. Korea	N	5.0 x 10 ¹	2.2 x 10 ⁴
Standard Q	Standard Q COVID-19, SD Biosensor Inc./Rep. Korea	N	5.0 x 10 ¹	2.2×10^4
Sure-Status	Sure-Status COVID-19 Antigen Card Test, Premier Medical Corp./ India	N	5.0×10^2	2.8×10^5
Tigsun	Tingsun COVID-19 Ag Rapid test/ Beijin Tigsun Diagnostics Ltd./China	N	1.0 x 10 ³	5.6 x 10 ⁵
Wantai	Rapid SARS-CoV-2 Antigen test/ Wantai Biological Pharmacy Ltd./China	N	1.0×10^2	4.3 x 10 ⁴
Wondfo	Wondfo 2019-nCoV Antigen Test/ Guangzhou Wondfo Biotech/China	N	1.0 x 10 ³	5.6 x 10 ⁵




Figure 1: Heatmap comparing the LODs of 32 Ag-RDT using the Gamma (P.1), ancestral (B.1) and Alpha (B.1.1.7) variants. Data of the ancestral B.1 and Alpha partially taken from our previously published work (5,7). Blue colours indicated LODs fulfilling the DHSC and WHO criteria.